Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Evidence-based Guidelines for the Utilization of Immunostains in Diagnostic Pathology: Pulmonary Adenocarcinoma Versus Mesothelioma

Evidence-based Guidelines for the Utilization of Immunostains in Diagnostic Pathology:... RESEARCH ARTICLE Evidence-based Guidelines for the Utilization of Immunostains in Diagnostic Pathology: Pulmonary Adenocarcinoma Versus Mesothelioma Alberto M. Marchevsky, MD* and Mark R. Wick, MDw markers is available for the characterization of many Abstract: There are no firmly established guidelines for the use human neoplasms, and these reagents are now employed of antibodies in immunohistology as individual tests or panels. routinely in diagnosis. Although IHC has added con- Practicing pathologists must rely on information available in siderable objectivity to morphologic observations, it has individual publications, review articles, books, and internet- well-documented technical limitations. These include false based databases to develop diagnostic immunohistochemical positive and false negative results, representing variable algorithms for their individual practices. In contrast, other specificity and sensitivity in regard to selected differential 2,3 medical specialties have crafted many evidence-based practice diagnoses. Indeed, pragmatically speaking, no indivi- guidelines (EBG) that are widely used; these have helped to dual marker is exclusively associated with a single augment standardization and cost effectiveness. In particular, particular diagnostic entity. To overcome such problems, the use of several ‘‘epithelial’’ and ‘‘mesothelial’’ antibodies has the use of antibody panels rather than individual markers 4–6 been proposed to distinguish epithelioid malignant mesothelio- has been http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Evidence-based Guidelines for the Utilization of Immunostains in Diagnostic Pathology: Pulmonary Adenocarcinoma Versus Mesothelioma

Loading next page...
 
/lp/wolters-kluwer-health/evidence-based-guidelines-for-the-utilization-of-immunostains-in-HRN0D696hN
ISSN
1541-2016
DOI
10.1097/01.pai.0000213148.62525.9a
pmid
17525624
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Evidence-based Guidelines for the Utilization of Immunostains in Diagnostic Pathology: Pulmonary Adenocarcinoma Versus Mesothelioma Alberto M. Marchevsky, MD* and Mark R. Wick, MDw markers is available for the characterization of many Abstract: There are no firmly established guidelines for the use human neoplasms, and these reagents are now employed of antibodies in immunohistology as individual tests or panels. routinely in diagnosis. Although IHC has added con- Practicing pathologists must rely on information available in siderable objectivity to morphologic observations, it has individual publications, review articles, books, and internet- well-documented technical limitations. These include false based databases to develop diagnostic immunohistochemical positive and false negative results, representing variable algorithms for their individual practices. In contrast, other specificity and sensitivity in regard to selected differential 2,3 medical specialties have crafted many evidence-based practice diagnoses. Indeed, pragmatically speaking, no indivi- guidelines (EBG) that are widely used; these have helped to dual marker is exclusively associated with a single augment standardization and cost effectiveness. In particular, particular diagnostic entity. To overcome such problems, the use of several ‘‘epithelial’’ and ‘‘mesothelial’’ antibodies has the use of antibody panels rather than individual markers 4–6 been proposed to distinguish epithelioid malignant mesothelio- has been

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Jun 1, 2007

There are no references for this article.